Shots:
Italfarmaco & VeriSIM Life have entered into a strategic collaboration to discover & develop novel histone deacetylase (HDAC)-targeted therapeutic assets for neuromuscular, fibrotic, & rare diseases
As per the deal, VeriSIM Life will receive technology service fees, development, regulatory, & commercial milestone payments, and royalties on future commercial products, with the total potential value…
